11/26
06:43 am
adag
Adagene (NASDAQ:ADAG) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Medium
Report
Adagene (NASDAQ:ADAG) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
11/24
07:19 am
adag
Adagene (NASDAQ:ADAG) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Medium
Report
Adagene (NASDAQ:ADAG) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
11/15
10:32 am
adag
Adagene (NASDAQ:ADAG) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Low
Report
Adagene (NASDAQ:ADAG) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
11/13
07:11 am
adag
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology [Yahoo! Finance]
Medium
Report
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology [Yahoo! Finance]
11/13
07:00 am
adag
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Low
Report
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
10/31
07:00 am
adag
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Low
Report
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
10/3
02:37 pm
adag
Adagene (NASDAQ:ADAG) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Adagene (NASDAQ:ADAG) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/16
08:00 am
adag
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Low
Report
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
9/9
07:43 am
adag
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Medium
Report
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]